Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Xiamen
Clinical trial register · China

Clinical Trials in Xiamen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19212 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:17 UTC
19212
Studies in scope
all four open statuses
11805
Recruiting now
open to new participants
2029
Lead sponsors
across recruiting studies
Top sites
Xiamen 66 Zhangzhou 1 Haikou 1 Fuzhou 1
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
The First Affiliated Hospital of Xiamen University66 Merck Sharp & Dohme LLC36 Bristol-Myers Squibb11 BeOne Medicines10 AbbVie8 Clear sponsor filter
Site location
Xiamen66 Zhangzhou1 Haikou1 Fuzhou1
All 4 locations
Target enrolment
to

Trials with a site in Xiamen

66 of 19212 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
30
Xiamen
2026-11-11
Recruiting
68Ga-XHER2 PET/CT for HER2 Assessment
NCT07885436Solid Tumor (Excluding CNS), HER2, PET / CT
The First Affiliated Hospital of Xiamen University
Not applicable
80
Xiamen
2026-10-22
Recruiting
68Ga-XMFH01 PET/Fluorescence Imaging in Prostate Cancer
NCT07885423Prostate Cancer (Diagnosis), ACP3, PET / CT
The First Affiliated Hospital of Xiamen University
Not applicable
25
Xiamen
2026-10-21
Recruiting
The First Affiliated Hospital of Xiamen University
Observational
100
Xiamen
2026-10-20
Not yet open
40 Hz Audio-Visual Stimulation Therapy for AD
NCT07926438Alzheimer's Disease Related Dementia
The First Affiliated Hospital of Xiamen University
Not applicable
50
Xiamen
2026-10-15
Recruiting
Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL
NCT07778212DLBCL - Diffuse Large B Cell Lymphoma, Intermediate-High Risk, First-Line
DrugsPola-R-Chp·Orelabrutinib
The First Affiliated Hospital of Xiamen University
Not applicable
30
Xiamen
2026-08-30
Recruiting
The First Affiliated Hospital of Xiamen University
Not applicable
120
Xiamen
2026-08-01
Recruiting
Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL
NCT07749365DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma)
The First Affiliated Hospital of Xiamen University
Phase 2
53
Xiamen
2026-07-25
Recruiting
DLL3-Targeted PET/CT in Small Cell Lung Cancer
NCT07677787PET/CT, Small Cell Lung Cancer ( SCLC ), DLL3-targeted PET/CT, Delta-like Protein 3
The First Affiliated Hospital of Xiamen University
Not applicable
20
Xiamen
2026-05-09
Recruiting
GPC3-Targeted PET/CT in Hepatocellular Carcinoma
NCT07677774Hepatocellular Carcinoma (HCC), Glypican-3, GPC3-targeted PET/CT
The First Affiliated Hospital of Xiamen University
Not applicable
40
Xiamen
2026-05-01
Recruiting
GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
NCT06875063Non-hodgkin Lymphoma, Refractory Lymphoma, Chimeric Antigen Receptor T-cell
The First Affiliated Hospital of Xiamen University
Phase 1
45
Xiamen
2026-04-30
Recruiting
Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease
NCT07547930Thyroid Eye Disease, TED, Graves Ophthalmopathy, Graves Orbitopathy
DrugTofacitinib
The First Affiliated Hospital of Xiamen University
Phase 2
8
Xiamen
2026-04-24
Not yet open
The First Affiliated Hospital of Xiamen University
Not applicable
60
Xiamen
2026-04
Recruiting
Human Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles for the Treatment of Dry Eye Disease
NCT07623382Dry Eye Disease, Umbilical Cord Mesenchymal Stem Cell-derived Small Extracellular Vesicles
The First Affiliated Hospital of Xiamen University
Early Phase 1
20
Xiamen
2026-03-31
Recruiting
DLL3-Targeted PET/CT in Neuroendocrine Carcinoma
NCT07458906DLL3-expressing Tumors, PET / CT, Neuroendocrine Cancer
The First Affiliated Hospital of Xiamen University
Not applicable
80
Xiamen
2026-03-10
Recruiting
Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT06992739NSCLC (Advanced Non-small Cell Lung Cancer), EGFR, Myelosuppression
The First Affiliated Hospital of Xiamen University
Phase 2
49
Xiamen
2025-12-08
Recruiting
The First Affiliated Hospital of Xiamen University
Not applicable
112
Xiamen
2025-11-01
Not yet open
The Effect of Semaglutide on Bone Health
NCT07165158Osteoporosis, Osteoporosis Fracture, T2DM
DrugsMetformin·Semaglutide
The First Affiliated Hospital of Xiamen University
Phase 4
150
Xiamen
2025-09-15
Recruiting
68Ga-XACP3 PET/CT in Prostate Cancer
NCT07242014Prostate Cancer, PET/CT, ACP3
The First Affiliated Hospital of Xiamen University
Not applicable
60
Xiamen
2025-09-01
Recruiting
Precise Guidance of Adaptive Radiotherapy for Nasopharyngeal Carcinoma
NCT07137052Nasopharyngeal Carcinoma (NPC), PET / CT
The First Affiliated Hospital of Xiamen University
Observational
732
Xiamen
2025-08-30
Not yet open
The First Affiliated Hospital of Xiamen University
Phase 2
34
Xiamen
2025-08-20
Recruiting
Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC
NCT07085234Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy, Induction Therapy
The First Affiliated Hospital of Xiamen University
Phase 2
30
Xiamen
2025-07-30
By invitation
Ultrasound Assessment of Fetal Growth Parameters
NCT07018362Fetal Clavicle Length, Fetal Scapular Width, Fetal Sternal Length, Fetal Scapular Length
The First Affiliated Hospital of Xiamen University
Observational
1,000
Xiamen
2025-07-01
Not yet open
The First Affiliated Hospital of Xiamen University
Phase 2
43
Xiamen
2025-06-30
Active, closed
The First Affiliated Hospital of Xiamen University
Phase 1/2
79
Xiamen
2025-06-29
Active, closed
The First Affiliated Hospital of Xiamen University
Phase 1/2
95
Xiamen
2025-06-26
Recruiting
The First Affiliated Hospital of Xiamen University
Observational
75
Xiamen
2025-06-22
Recruiting
The First Affiliated Hospital of Xiamen University
Observational
113
Xiamen
2025-05-09
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
33
Xiamen
2025-05-09
Recruiting
PET/CT for Trop2 ADC Response Evaluation NSCLC
NCT07151898NSCLC, Trop2, PET/CT
The First Affiliated Hospital of Xiamen University
Observational
50
Xiamen
2025-05-01
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 1
30
Xiamen
2025-03-15
Recruiting
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
NCT06811844Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy, Complete Response
The First Affiliated Hospital of Xiamen University
Phase 2
208
Xiamen, Zhangzhou, Haikou
2025-02-25
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
30
Xiamen
2025-02-08
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 1
18
Xiamen
2024-12-12
Recruiting
68Ga-MY6349 PET/CT in Solid Tumors
NCT07046702Solid Tumor, Trop2, PET/CT
The First Affiliated Hospital of Xiamen University
Observational
300
Xiamen
2024-12-10
By invitation
IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma
NCT06688175Nasopharyngeal Neoplasms, Elderly, Chemotherapy
DrugIMRT
The First Affiliated Hospital of Xiamen University
Phase 2
32
Xiamen
2024-11-13
Recruiting
A Clinical Follow-up Study on the Efficacy of Thumbtack Needle for Postoperative Sleep and Recovery Treatment
NCT06757023Postoperative Complications, Postoperative Pain, Acupuncture
The First Affiliated Hospital of Xiamen University
Observational
110
Xiamen
2024-11-13
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
20
Xiamen
2024-11-05
Recruiting
PET/CT for Trop2 ADC Response Evaluation Cancers
NCT07046689Breast Cancer, Trop2, PET/CT
The First Affiliated Hospital of Xiamen University
Observational
50
Xiamen
2024-11-01
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
22
Xiamen
2024-10-21
Recruiting
A Multicenter Study Evaluating the Diagnostic Value of 68Ga-MY6349 PET/CT for Prostate Cancer
NCT06696326Positron-Emission Tomography(PET), Prostate Cancer, Trophoblast Cell Surface Antigen 2
The First Affiliated Hospital of Xiamen University
Not applicable
100
Xiamen
2024-10-01
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
5
Xiamen
2024-09-24
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
50
Xiamen
2024-09-01
Recruiting
The First Affiliated Hospital of Xiamen University
Not applicable
36
Xiamen
2024-06-23
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 1
20
Xiamen
2024-06-12
Recruiting
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
NCT06387056Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer
DrugsPamiparib·Rezvilutamide·Tislelizumab·Docetaxel
The First Affiliated Hospital of Xiamen University
Phase 2
40
Xiamen
2024-04-01
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
39
Xiamen
2024-03-31
Recruiting
The First Affiliated Hospital of Xiamen University
Observational
90
Xiamen
2023-11-22
Recruiting
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
NCT06151106Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma
DrugChidamide
The First Affiliated Hospital of Xiamen University
Phase 2
33
Xiamen
2023-11-22
Recruiting
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
NCT06151080DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma
DrugsG-Chop·Lenalidomide
The First Affiliated Hospital of Xiamen University
Phase 2
38
Xiamen
2023-11-22
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
25
Xiamen
2023-11-22
Recruiting
AZA Combined With RCHOP in P53-mutated DLBCL.
NCT06158399DLBCL - Diffuse Large B Cell Lymphoma, TP53
DrugsR-Chop·Azacitidine
The First Affiliated Hospital of Xiamen University
Phase 2
52
Xiamen
2023-11-22
Recruiting
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
NCT06158386Follicular Lymphoma, Refractory B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
DrugsLinperlisib·Chidamide
The First Affiliated Hospital of Xiamen University
Phase 2
33
Xiamen
2023-11-22
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
71
Xiamen
2023-11-15
Recruiting
The First Affiliated Hospital of Xiamen University
Not applicable
120
Xiamen
2023-09-01
Recruiting
The First Affiliated Hospital of Xiamen University
Observational
100
Xiamen
2023-05-30
Recruiting
The First Affiliated Hospital of Xiamen University
Not applicable
30
Xiamen
2023-04-09
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
66
Xiamen
2022-12-01
Recruiting
The First Affiliated Hospital of Xiamen University
Phase 2
66
Xiamen
2022-07-01
Recruiting
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
NCT05305859Leukemia, Myeloid, Acute, Relapsed Adult AML, Refractory Leukemia
The First Affiliated Hospital of Xiamen University
Phase 2
30
Xiamen
2022-01-12
Active, closed
Time Restricted Eating on Impaired Glucose Regulation(TRIG Trial)
NCT03802253Impaired Glucose Regulation, Overweight/Obese, Time-restricted Eating
The First Affiliated Hospital of Xiamen University
Not applicable
142
Xiamen
2020-05-04
Recruiting
Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children
NCT06530004Nephrotic Syndrome, Rituximab, Children, Efficacy
DrugRituximab
The First Affiliated Hospital of Xiamen University
Observational
50
Xiamen
2020-03-01
Recruiting
Comparison of FDG and FAPI in Patients With Various Types of Cancer
NCT04416165Tumor, Solid, Positron-Emission Tomography, Metastasis
The First Affiliated Hospital of Xiamen University
Not applicable
3,000
Xiamen
2019-10-20
Recruiting
The First Affiliated Hospital of Xiamen University
Observational
10,000
Xiamen
2019-03-20
Recruiting
Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)
NCT03087032Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)
DrugsInsulin glargine·Liraglutide
The First Affiliated Hospital of Xiamen University
Phase 4
164
Xiamen
2019-01-10
Recruiting
The First Affiliated Hospital of Xiamen University
Not applicable
140
Xiamen
2018-02-15
Rows per page Showing 1–66 of 66
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 November 2026. https://priyalifescience.com/clinical-trials-china/city/xiamen

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,212 studies in total at the last sync on 10 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 66 of those studies with a site in Xiamen that also match the filters currently applied.

How many clinical trials are recruiting in Xiamen?

56 of the 66 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:17 UTC sync. A further 5 have not yet opened recruitment, 3 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Xiamen), 66 studies
PhaseStudiesRecruitingShare
Phase 2262339.4%
Not applicable181527.3%
Observational131219.7%
Phase 1446.1%
Phase 1/2203%
Phase 4213%
Early Phase 1111.5%

Most active sponsors

Lead sponsors with the most studies (Xiamen)
Lead sponsorStudiesRecruiting
The First Affiliated Hospital of Xiamen University6656
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.